10-K: EDAP TMS Reports 2025 Financials, Advances HIFU Technology

EDAP TMS S.A. reported a 1.6% increase in total revenues to $70.5 million in 2025, driven by strong HIFU growth, while facing a net loss of $29.2 million and strategic shifts away from legacy businesses.

Summary

• Total revenues increased 1.6% to $70.5 million in 2025 from $69.4 million in 2024.
• HIFU division revenues grew 44.8% to $37.4 million in 2025, with 35 Focal One units sold (20 in the U.S.).
• ESWL division revenues decreased 23.2% to $7.5 million in 2025 due to the discontinuation of new system sales.
• Distribution division revenues decreased 24.1% to $25.7 million in 2025 due to termination of agreements.
• Gross profit increased to $30.0 million (42.5% of net sales) in 2025 from $28.7 million (41.4% of net sales) in 2024.
• Operating expenses increased 7.3% to $54.7 million in 2025, driven by R&D and G&A.
• Net loss widened to $29.2 million in 2025 from $20.6 million in 2024.
• Cash and cash equivalents decreased by $10.5 million to $20.5 million as of December 31, 2025.
• Received FDA 510(k) clearance for the latest Focal One Robotic HIFU evolution in November 2025, including next-generation ultrasound imaging designed to support future AI-driven algorithms.
• Granted Breakthrough Device designation by the FDA for deep infiltrating endometriosis (DIE) treatment on March 13, 2024.
• Received CE Mark for the treatment of posterior deep endometriosis infiltrating the rectum and surrounding structures on March 26, 2025.
• The Landmark HIFI Study reported Focal One Robotic HIFU is non-inferior to surgery for Salvage Treatment-free Survival at 30 months, with better urinary continence and erectile function outcomes.
• The FARP Randomized Controlled Trial demonstrated non-inferiority of Focal Ablation to Radical Prostatectomy for treatment failure at 36 months.
• The Multicenter CGRD Study showed HIFU non-inferior to EBRT for overall and cancer-specific survival at 10 years, with improved OS in stage IIa prostate cancer.
• French Ministry of Health awarded national reimbursement for HIFU procedures for prostate cancer, effective September 1, 2025.
• The AMA established a new CPT Category III code, CPT 0950T, for transrectal HIFU for the treatment of BPH, effective July 1, 2025.
• CMS assigned CPT 0950T to Urology APC level 6, establishing a national average facility reimbursement of $9,671 per procedure for Medicare BPH patients.
• Total indebtedness was $24.5 million as of December 31, 2025, including $6.9 million outstanding under the EIB Loan and $8.1 million fair value of Tranche A Warrants.
• Management intends to draw Tranche B of the €36.0 million Credit Facility with the European Investment Bank (EIB) for €12.0 million in April 2026.
• Remediated previously identified material weaknesses in internal control over financial reporting within the U.S. subsidiary as of December 31, 2025.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mixed filing with strong strategic and clinical progress in HIFU, but continued and widening net losses, significant cash burn, and increased financial expenses indicate ongoing financial challenges and reliance on future capital raises.

Positives

• HIFU division revenue increased by 44.8% to $37.4 million in 2025, reflecting strong growth in equipment sales and treatment-driven revenue.
• FDA 510(k) clearance for the latest Focal One Robotic HIFU evolution in November 2025, including next-generation ultrasound imaging to support AI development.
• Breakthrough Device designation by the FDA for deep infiltrating endometriosis (DIE) treatment in March 2024.
• CE Mark for the treatment of posterior deep endometriosis infiltrating the rectum and surrounding structures in March 2025.
• The Landmark HIFI Study showed Focal One Robotic HIFU is non-inferior to surgery for Salvage Treatment-free Survival at 30 months, with better urinary continence and erectile function.
• The FARP Randomized Controlled Trial demonstrated non-inferiority of Focal Ablation to Radical Prostatectomy for treatment failure at 36 months.
• The Multicenter CGRD Study showed HIFU non-inferior to EBRT for overall and cancer-specific survival at 10 years, with improved overall survival in stage IIa prostate cancer.
• French Ministry of Health awarded national reimbursement for HIFU procedures for prostate cancer, effective September 1, 2025, with favorable bundled payment rates.
• The AMA established a new CPT Category III code (CPT 0950T) for transrectal HIFU for BPH, effective July 1, 2025, expanding the addressable market.
• CMS assigned CPT 0950T to Urology APC level 6, establishing a national average facility reimbursement of $9,671 per procedure for Medicare BPH patients.
• Gross margin increased to 42.5% in 2025 from 41.4% in 2024, primarily due to HIFU growth and favorable fixed cost absorption.
• Remediation of previously identified material weaknesses in internal control over financial reporting as of December 31, 2025.

Negatives

• Net loss widened to $29.2 million in 2025 from $20.6 million in 2024.
• Operating losses have been incurred in each fiscal year since 2021 and are expected to continue in the foreseeable future.
• Cash and cash equivalents decreased by $10.5 million to $20.5 million as of December 31, 2025.
• ESWL division total revenues decreased 23.2% from $9.7 million in 2024 to $7.5 million in 2025, primarily due to the strategic decision to stop selling the Sonolith i-move lithotripsy product line.
• Distribution division total revenues decreased 24.1% from $33.9 million in 2024 to $25.7 million in 2025, primarily due to the termination of distribution agreements.
• Operating expenses increased 7.3%, or $3.7 million, from $51.0 million in 2024 to $54.7 million in 2025, outpacing revenue growth.
• Net financial expense was $3.1 million in 2025, compared with a net financial income of $0.6 million in 2024, primarily driven by the variation of the fair value of EIB warrants ($2.6 million expense) and interest expense of the EIB loan ($0.3 million).
• Recorded a net foreign currency exchange loss of $1.0 million in 2025, compared to a gain of $1.3 million in 2024.
• Did not comply with the Equity Ratio Covenant with Banque Palatine as of December 31, 2025, which qualified as an event of default under the EIB Finance Contract, though waivers were subsequently obtained.

Risks

• Inability to obtain additional financing when needed could adversely affect the ability to continue as a company.
• Future revenue and income growth depends largely on the success of HIFU technology and the capacity to scale operations.
• Changes in U.S. trade policy, including the imposition of tariffs, may have a material adverse impact on business and results of operations.
• Operating cash flow is highly dependent on cyclical demand for products, leading to significant fluctuations.
• Substantial debt ($24.5 million as of December 31, 2025) could impair flexibility and access to capital and adversely affect financial position.
• Servicing debt requires a significant amount of cash, and there is no assurance of sufficient cash flow from business to pay substantial debt.
• Exercise of warrants issued to the European Investment Bank (EIB) may dilute the ownership interest of shareholders or otherwise depress the market price of ADSs.
• Failure to successfully optimize sales, marketing, and distribution channels or maintain high product quality and reliability may negatively impact operating results.
• New device developments and introductions may adversely impact financial results if not successful or well-received by customers.
• Potential issues in the adoption and use of AI in product offerings may result in reputational harm or liability.
• Future success depends on obtaining and maintaining government regulatory approval of products, which may be delayed or not received.
• Clinical trials related to products using HIFU technology may not be successful, and regulatory approvals necessary for commercialization may not be obtained.
• Commercial success of products depends on whether procedures performed using those products are eligible for reimbursement approved by national health authorities and third-party payers.
• HIFU technology may not be widely adopted by the medical community and may never become a standard of care.
• Products or service offerings could become obsolete or uncompetitive due to intense competition and rapid technological development.
• Revenue may be disrupted due to the strategic shift to focus on HIFU activities and away from legacy non-HIFU activities.
• Significant risk of exposure to product liability claims in the event that the use of products results in personal injury or death, and insurance coverage may be inadequate.
• Dependence on a single site to manufacture products (Vaulx-en-Velin, France) means any interruption of operations could have a material adverse effect.
• Reliance on a small number of suppliers for key components and services exposes the company to supply shortages, obsolescence, or cost increases.
• Utilization of distributors for international sales subjects the company to risks related to distributor actions, compliance with anti-corruption laws, and potential lawsuits.
• As a relatively small company, sales fluctuations and employee turnover may adversely affect business.
• Loss of key members of the executive management team could adversely affect business.
• Difficulties in attracting and recruiting highly qualified experts in hardware, software, AI, design, and development of high technology devices.
• Exposure to risks related to cybersecurity threats and incidents, which could result in business disruption, data loss, reputational damage, and increased costs.
• The expansion of social media platforms and new technologies presents risks and challenges for business and reputation.
• Disruption in intellectual property protection due to expiring patents and lack of updated filings.
• U.S. laws relating to the patentability of certain inventions in the life sciences and medical technology industry are uncertain and rapidly changing.
• Inability to protect or enforce intellectual property rights throughout the world.
• Use of open-source software could negatively affect the ability to sell products and subject the company to possible litigation.
• French and international operations expose the company to additional costs, legal, and regulatory risks.
• Business is affected by fluctuations in currency exchange rates, particularly between the euro, U.S. dollar, and Japanese yen.
• By-laws and French corporate law contain provisions that may delay or discourage a takeover attempt.
• The rights of shareholders in companies subject to French corporate law differ in material respects from the rights of shareholders of corporations incorporated in the United States.
• French law may limit the amount of dividends the company is able to distribute, and there is no current intention to pay dividends.
• Judgments of U.S. courts, including those predicated on the civil liability provisions of the federal securities laws of the United States, may not be enforceable in French courts.
• Securities may be affected by volume fluctuations and may fluctuate significantly in price, causing investors to lose some or all of their investment.
• Holders of ADSs have fewer rights than direct shareholders and must act through the Depositary to exercise those rights.
• If securities or industry analysts do not publish research, or publish inaccurate or unfavorable research, about the market or business, ADS price and trading volume could decline.
• Subject to different corporate disclosure standards as a U.S. Domestic Issuer, which may limit the information available to holders of ADSs.
• Preferential subscription rights may not be available for U.S. persons, leading to dilution.
• Results of operations and financial condition could be adversely affected by adverse economic changes, political, social, and geopolitical developments, financial changes, and the impact of climate change.
• Global potential inflation may have a material adverse effect on business, results of operations, and financial condition.
• May issue additional securities that may be dilutive to existing shareholders, in view of funding new developments and accelerating business expansion.
• May in the future be the target of securities class action or other litigation, which could be costly and time consuming to defend.

Future Outlook

The company plans to pursue potential expansion of clinical indications for the Focal One platform beyond prostate cancer, to include benign prostatic hyperplasia (BPH) and endometriosis. Research and development efforts are focused on advancing imaging and targeting precision, integrating next-generation automation and software intelligence (including AI), and expanding into new urologic and non-urologic therapeutic indications. Management expects marketing, selling, and R&D expenses to increase as they further develop and commercialize HIFU devices. The company intends to draw Tranche B of its EIB Credit Facility in April 2026 and believes it will have sufficient funds for at least twelve months from the report date, but will need substantial additional financing thereafter to meet cash flow needs and achieve profitability.

Management Comments

• Our realignment is intended to position Focal One HIFU as a differentiated platform that we believe may support higher-margin growth opportunities over time.
• We believe these expanded indications could result in Focal One's total addressable market expansion, resulting in a stronger business case for healthcare providers and increased revenue for the company.
• Our R&D investment strategy is intended to create a durable innovation cycle that supports clinical leadership, regulatory expansion, and commercial adoption.
• With increasing physician demand for non-invasive, tissue-sparing prostate therapy, a rapidly growing evidence base, and expanding capabilities in precision robotics and AI, we believe our R&D strategy is focused on advancing our Focal One i System and expanding its potential clinical applications over time.
• We believe our employee relations are positive.
• We believe that this strategic focus will position us for stronger, sustainable growth, the execution of this transition may involve significant risks that could materially impact our financial performance and shareholder value in the short term.
• We intend to draw Tranche B of its Credit Facility with EIB for 12 million in April 2026 on the basis that we believe that we have or are able to satisfy to all condition precedents to draw this second tranche at the date this annual report is issued.
• With these additional proceeds, we believe we will have sufficient funds to support our operations for at least a period of twelve months from the date of issue of this annual report.

Industry Context

StockSavvy.ai notes that EDAP TMS is strategically positioning itself in the growing market for non-invasive therapeutic ultrasound and energy-based medical devices, particularly in urology and women's health. The company's exclusive focus on High Intensity Focused Ultrasound (HIFU) technology aligns with a broader industry trend towards minimally invasive procedures and precision medicine. The efforts in AI integration and expanded indications (Benign Prostatic Hyperplasia, endometriosis) reflect a proactive approach to capture larger addressable markets and differentiate from traditional surgical and radiation therapies. The increasing adoption of active surveillance for low-risk prostate cancer also creates a demand for effective, less morbid focal therapies like HIFU, which EDAP TMS aims to address with its Focal One platform.

Comparison to Industry Standards

• The Landmark HIFI Study reported Focal One Robotic HIFU is non-inferior to radical prostatectomy surgery for Salvage Treatment-free Survival at 30 months, with better urinary continence and erectile function outcomes.
• The FARP Randomized Controlled Trial demonstrated non-inferiority of Focal Ablation to Radical Prostatectomy for treatment failure at 36 months.
• The Multicenter CGRD Study showed HIFU non-inferior to external beam radiotherapy (EBRT) for overall and cancer-specific survival at 10 years, with significantly improved overall survival in stage IIa prostate cancer. HIFU also offers the benefit of a single outpatient procedure compared to 37-45 visits for radiation therapy.
• U.S. national average physician payment for HIFU (CPT 55880) is $884, which compares favorably to alternative ablative treatments for prostate cancer such as cryotherapy ($692), irreversible electroporation ($675), and transurethral thermal ultrasound ablation ($530), but is lower than laparoscopic or robotic radical prostatectomy ($1,087).
• French national healthcare system bundled payment rates for HIFU in the public sector (ranging from €7,762.50 to €13,082.72) exceed surgical rates at level 1 and level 2 complexity tiers. In the private sector, HIFU reimbursement (ranging from €6,061.53 to €8,601.91) exceeds surgical rates at all levels.
• Competitors in the HIFU space include Sonablate Corporation (Sonablate system), Profound Medical Corp. (TULSA-PRO system), and Insightec Ltd. (Exablate system). Other competitors develop alternative focal therapy approaches including laser ablation, irreversible electroporation, and other image-guided or energy-based technologies.

Management Changes

Corporate Governance

Legal Proceedings

• No pending legal proceedings were reported.

Related Party Transactions

• On August 19, 2019, EDAP Technomed Co. Ltd. (Japan) contracted a JPY 80,000,000 loan, personally guaranteed by Mr. Jean-François Bachelard (representative director, president, and CEO of the subsidiary). EDAP TMS S.A. counter-guaranteed this personal loan and agreed to indemnify Mr. Bachelard in an indemnification letter dated September 12, 2019, expiring upon loan maturity date of August 26, 2026.
• On April 22, 2020, EDAP Technomed Co. Ltd. (Japan) contracted a JPY 50,000,000 loan, personally guaranteed by Mr. Jean-François Bachelard. EDAP TMS S.A. counter-guaranteed this personal loan and agreed to indemnify Mr. Bachelard in an indemnification letter dated June 2, 2020, expiring upon loan maturity date of April 2, 2025.

Stakeholder Impact

• Shareholders: Potential dilution from future equity raises and EIB warrants; increased transparency as a U.S. domestic issuer; continued net losses and cash burn may concern investors; positive clinical results and reimbursement expansion could drive long-term value.
• Employees: New Executive Severance Plan provides benefits upon qualifying termination; ongoing focus on recruitment, retention, professional development, and wellbeing; potential for equity-based awards; increased R&D activities may create new opportunities.
• Customers (Hospitals/Clinics): Expanded clinical indications for Focal One (BPH, endometriosis) offer new treatment options; improved reimbursement in France and U.S. for HIFU procedures enhances accessibility; new Focal One i System with AI-driven algorithms aims to improve surgical assistance and treatment evaluation.
• Suppliers: Strategic shift away from ESWL and Distribution businesses may impact relationships with certain third-party suppliers and distributors; reliance on a small number of suppliers for key components poses supply chain risks.
• Creditors (EIB, Banque Palatine): Debt covenants and waivers obtained from EIB and Banque Palatine indicate ongoing monitoring of financial health; EIB Credit Facility provides capital for R&D.

Next Steps

• Submit the full manuscript of the FARP trial for publication in a peer-reviewed journal in 2026.
• Submit the full manuscript of the HIFI-2 study for publication in a peer-reviewed journal in 2026.
• Draw Tranche B of the EIB Credit Facility for €12.0 million in April 2026.
• Potentially request disbursement of Tranche C borrowings (€13.0 million) within 30 months following the Effective Date (October 17, 2025), upon satisfaction of certain conditions.
• Continue R&D efforts to enhance imaging and targeting precision, integrate next-generation automation and software intelligence (including AI), and expand into new urologic (BPH) and non-urologic (endometriosis) therapeutic indications.
• Continue to pursue expanded reimbursement coverage in additional European markets.
• Annual general meeting to ratify Mr. David Horn's provisional appointment to the Board of Directors.
• Payment of short-term incentive compensation for the performance period ending December 31, 2025, is expected to be made in May 2026.

Key Dates

Recommendation

EDAP TMS shows strong potential with its HIFU technology, evidenced by positive clinical trial results, FDA Breakthrough Device designation, and expanded reimbursement in key markets. The strategic shift to focus on higher-margin HIFU activities is a sound long-term move. However, the company continues to incur significant net losses and cash burn, necessitating further capital raises. While the EIB facility provides some liquidity, the overall financial position remains challenging. The stock is a 'hold' for seasoned investors due to the promising technology and market expansion potential, balanced against the current financial losses and execution risks associated with scaling a medical technology company and transitioning away from legacy revenue streams.

Keywords

HIFU, Focal One, Prostate Cancer, Endometriosis, Medical Devices, Robotic Surgery, Ultrasound Technology, FDA Clearance, CE Mark, Reimbursement, Clinical Trials, Biotechnology, Healthcare, SEC Filing, 10-K, EDAP TMS, Urology, Womens Health, AI, Artificial Intelligence, Capital Raise, Debt Financing, Intellectual Property, Shareholder Rights, Corporate Governance